Manufacturer of Controlled Substances; Notice of Application, 45784-45785 [E8-17963]

Download as PDF 45784 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: July 30, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–18065 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 28, 2008, Chattem Chemicals Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application mstockstill on PROD1PC66 with NOTICES Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2008, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to manufacture small quantities of the above listed controlled substance for distribution to its customers for the purpose of research. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 28, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17955 Filed 8–5–08; 8:45 am] 4-Methoxyamphetamine (7411) .... Difenoxin (9168) ........................... Amphetamine (1100) .................... Methamphetamine (1105) ............. Methylphenidate (1724) ................ Pentobarbital (2270) ..................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Meperidine (9230) ......................... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Noroxymorphone (9668) ............... Alfentanil (9737) ............................ Sufentanil (9740) .......................... Fentanyl (9801) ............................. 16:46 Aug 05, 2008 Jkt 214001 II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17961 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P VerDate Aug<31>2005 I I II II II II II II II II II PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2008, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedule II. The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17962 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 28, 2008, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Methadone (9250) ........................ E:\FR\FM\06AUN1.SGM 06AUN1 Schedule II II II II 45785 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices Drug Schedule Methadone intermediate (9254) ... II The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17963 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 11, 2008, American Radiolabeled Chemical, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: mstockstill on PROD1PC66 with NOTICES Drug Schedule Gamma hydroxybutyric acid (2010). Ibogaine (7260) ............................. Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ...... Dimethyltryptamine (7435) ............ 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470). Dihydromorphine (9145) ............... Normorphine (9313) ...................... Amphetamine (1100) .................... Methamphetamine (1105) ............. Amobarbital (2125) ....................... Phencyclidine (7471) .................... Phenylacetone (8501) ................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................. VerDate Aug<31>2005 16:46 Aug 05, 2008 I I I I I I I I II II II II II II II II II II Jkt 214001 Drug Schedule Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Meperidine (9230) ......................... Metazocine (9240) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Oxymorphone (9652) .................... Phenazocine (9715) ...................... Fentanyl (9801) ............................. II II II II II II II II II II II The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17971 Filed 8–5–08; 8:45 am] Drug Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Schedule II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration. Any other such applicant, and any person who is presently, registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 30, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator/Deputy Chief of Operation, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–18046 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 23, 2008, Austin Pharma, LLC., 811 Paloma Drive, Suite A, Round Rock, Texas 78665– 2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Alphamethadol (9605) .................. Nabilone (7379) ............................ Methadone (9250) ........................ Methadone Intermediate (9254) ... Levo-alphacetylmethadol (9648) .. Alfentanil (9737) ........................... PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 I I I II II II II II Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 27, 2008, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ E:\FR\FM\06AUN1.SGM 06AUN1 Schedule I II II II II II II II II II II

Agencies

[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Pages 45784-45785]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17963]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 28, 2008, Boehringer 
Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 
23805, made application by renewal to the Drug Enforcement 
Administration (DEA) as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100)..........................  II
Lisdexamfetamine (1205).....................  II
Methylphenidate (1724)......................  II
Methadone (9250)............................  II

[[Page 45785]]

 
Methadone intermediate (9254)...............  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers for formulation into finished 
pharmaceuticals.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 6, 2008.

    Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-17963 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.